Pre-orders of COVID-19 vaccine top five billion | Inquirer News

Pre-orders of COVID-19 vaccine top five billion

/ 03:42 PM August 12, 2020

Although none of the coronavirus vaccines under development has proved its efficacy yet in clinical trials, at least 5.7 billion doses have been pre-ordered around the world.

First shipments of a COVID-19 vaccine created by Western laboratories have often been snapped up by the United States.

Five vaccines — three Western and two Chinese — are in Phase 3 efficacy trials involving thousands of people.

ADVERTISEMENT

In a surprise announcement, Russian President Vladimir Putin claimed Tuesday that a vaccine dubbed “Sputnik V” — after the Soviet satellite — conferred “sustainable immunity” against the novel coronavirus.

FEATURED STORIES

As research laboratories around the world race to develop a vaccine, manufacturers have received financing to help them prepare to have millions of doses ready to administer in 2021 or even before the end of the year.

Oxford University, working with the Swedish-British pharmaceutical group AstraZeneca, hopes to have results by September while the US biotech company Moderna, partnering with the US National Institutes of Health (NIH), is aiming for the end of the year, possibly November.

US: 700 million doses

Lisa Taylor receives a COVID-19 vaccination from RN Jose Muniz as she takes part in a vaccine study at Research Centers of America on August 07, 2020 in Hollywood, Florida. Research Centers of America is currently conducting COVID-19 vaccine trials, implemented under the federal government’s Operation Warp Speed program. Joe Raedle/Getty Images/AFP

President Donald Trump has launched “Operation Warp Speed” in a bid to develop, manufacture and distribute a COVID-19 vaccine to all Americans by January 2021.

Hundreds of millions of dollars have been directed to vaccine developers including nearly $500 million to Johnson & Johnson at the end of March.

The United States has allocated funding to more companies than other nation in the hope that one of them will come up with the vaccine to counter the highly contagious virus.

So far, Washington has handed out at a total of least 9.4 billion dollars to seven vaccine developers and signed manufacturing contracts with five of them to provide 700 million doses.

ADVERTISEMENT

The companies involved are: Johnson & Johnson, Moderna, Oxford/AztraZeneca, Novavax, Pfizer/BioNTech, Sanofi/GSK, Merck Sharp and Dohme.

Europe: 700 million doses

France vaccine

French engineer-virologist Thomas Mollet looks at 24 well plates adherent cells monolayer infected with a Sars-CoV-2 virus at the Biosafety level 3 laboratory (BSL3) of the Valneva SE Group headquarters in Saint-Herblain, near Nantes, western France, on July 30, 2020. (Photo by JEAN-FRANCOIS MONIER / AFP)

Two vaccine developers — Oxford/AztraZeneca and Sanofi/GSK — have signed or are in advanced negotiations with the European Commission to provide a combined 700 million vaccine doses.

Britain, Japan, Brazil

Novavax

Three potential coronavirus, COVID-19, vaccines are kept in a tray at Novavax labs in Gaithersburg, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19. (Photo by ANDREW CABALLERO-REYNOLDS / AFP) /  require.”

Britain, because of Brexit, is negotiating a separate pre-order of 250 million doses from four developers.

Japan is counting on 490 million doses from three suppliers including 250 million from Novavax of the United States.

Japanese pharmaceutical giant Takeda bought the rights to a Novavax vaccine for Japan, which has funded the research. It would be produced locally.

Brazil chose a similar model, ordering 100 million doses from AstraZeneca, and partnering with China’s Sinovac to produce 120 millions of “CoronaVac,” which is already undergoing testing with Brazilians.

China, Russia

Sinovac

A doctor shows the box of a COVID-19 vaccine produced by Chinese company Sinovac Biotech at the Sao Lucas Hospital, in Porto Alegre, southern Brazil on August 08, 2020. – The vaccine trial is being carried out in Brazil in partnership with Brazilian Research Institute Butanta. (Photo by SILVIO AVILA / AFP)

Clinical tests of two Chinese vaccine candidates — Sinovac and Sinopharm — are well underway but only a few international partnerships have been announced, the one with Brazil and a possible one with Indonesia.

Russia said 20 nations have pre-ordered one billion doses of Sputnik V and that with foreign partners it would be able to produce 500 million doses a year in five countries.

Developing countries

The Coalition for Epidemic Preparedness Innovations (CEPI), launched in 2017 by Norway, India, the Bill and Melinda Gates Foundation and the Wellcome Trust, seeks to ensure that there is “equitable access” to future vaccines.

It has pre-ordered 300 million doses from AstraZeneca for dozens of developing countries in a partnership with The Vaccine Alliance (Gavi).

Billions of doses would be produced for Asia and elsewhere by the giant Serum Institute of India (SII), the largest vaccine producer in the world.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

Novavax and AstraZeneca have separately signed agreements with SII to produce a billion doses each for India and low- and middle-income countries on the condition, of course, that they prove their efficacy in clinical trials.

CFC

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: China, COVID-19, Europe, Health, Russia, United States, world

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.